<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Resting heart rate represents a cardiovascular risk indicator and an important target of therapy in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> and potentially in <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical and experimental evidence suggests that sustained elevation of heart rate - independent of the underlying trigger - plays a causal role in the pathogenesis of <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Results of the SHIFT trial support the importance of heart-rate reduction with ivabradine for improvement of clinical outcomes in <z:hpo ids='HP_0001635'>heart failure</z:hpo> and confirm the role of heart rate as a risk factor for patients with severe left ventricular dysfunction </plain></SENT>
<SENT sid="3" pm="."><plain>Results of the BEAUTIFUL trial show that patients with <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> and a heart rate above 70Â bpm exhibit an adverse prognosis concerning coronary events </plain></SENT>
</text></document>